DPD-5FU
| DPD-5FU (DPD for 5-fluorouracil toxicity) | |||
| DPD-5FU, DPD deficiency, 5-fluorouracil toxicity | |||
| Whole blood, EDTA, 3.7ml (red). Upon arrival in the laboratory the sample is stored refrigerated prior to referral | |||
|
Cambridge Genomic Laboratory Box 143 ATC Level 6 Cambridge University Hospital Foundation Trust Addenbrooke's Hospital, Hills Road, Cambridge, CB2 0QQ 01223 348866 Turnaround time 6 weeks |
|||
| The fluoropyrimidine drugs capecitabine and 5-fluorouracil are widely used for the treatment of solid tumours, including colorectal and metastatic breast cancers. Pharmacogenetic variation in the DPYD gene is associated with early, severe toxicity to fluoropyrimidine therapy. Testing should be done prior to the start of therapy and the starting dose adjusted according to DPYD genotype. Polymorphic variants in the DPYD gene are associated with severe, sometimes fatal, toxicity to fluoropyrimidine therapy. The NHS East Genomic Laboratory Hub (CUH) offers a DPYD panel of variants as a diagnostic test to predict fluoropyrimidine toxicity. | |||
| Contact referral laboratory for more information | |||
| N/A | |||
| N/A | |||
| N/A |
